Loading stock…

BeOne Medicines AG (ONC) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

BeOne Medicines AG

ONCMarket cap $40BPrice $350.1

Country🇨🇳China

SectorHealthcare

IndustryBiotechnology

Develops and sells cancer therapies worldwide, with its blood cancer drug Brukinsa now outselling rivals in a market once dominated by AbbVie and Johnson & Johnson. One of the few Chinese-founded biotechs competing head-to-head with Big Pharma globally.

In Bastion Portfolios?

52W Return+11%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+56%10

Revenue Forecast

Rev CAGR (1y)+27%9

Rev CAGR (3y)+18%9

Rev CAGR (5y)+15%9

Earnings Forecast

EPS Growth Y+1+194%10

EPS Growth Y+2+43%9

EPS Growth Y+3+33%9

Quality

Margins

EBIT Margin15%6

Net Income Margin11%6

Free Cash Flow Margin22%8

Debt

Net Debt/EBITDA-2.810

Efficiency

ROE15%6

ROA8%8

Earnings Stability44

GEAR+VERY STRONG88

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)431

P/E Ratio (Forward 3y)242

P/BV7.72

EV Multiples

EV/EBITDA Fwd311

EV/EBIT Fwd352

Yield

Free Cash Flow Yield3.3%5

Dividend Yieldna–

Momentum

Short term

1 month return-0%7

3 month return+16%9

YTD return+15%7

Mid term

Price vs 52wHigh91%8

1 year return+4%5

Long term

3 year return+103%8

5 year return-4%3

Risk Shield

Price Risk

Beta0.86

Volatility35%5

Free Cash Flow

Free Cash Flow Margin22%8

Free Cash Flow Yield3.3%5

Quality

ROCE17%8

Earnings Stability44

Net Debt/EBITDA-2.810

02Growth

Is it actually growing, and how fast?

ONCBeOne Medicines

Revenue FY25$5.3B

GROWTH RATING↗

VERY STRONG95 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+56%10

Revenue, next 1Y+27%9

Revenue, next 3Y, CAGR+18%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+194%10

EPS growth, FY27E+43%9

EPS growth, FY28E+33%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 95% of companies worldwide.

Revenue grew 56%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 18%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 43%/yr vs revenue 18%/yr), so margins should widen.

WATCH

Revenue grew 56%/yr over the last 3 years; forecasts see it cooling to 18%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

ONCBeOne Medicines

Total return Current1053%

Price return Current1053%

MOMENTUM RATING↗

STRONG73 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%7

3-month return+16%9

YTD return+15%7

MID & LONG-TERM▾SCORE

% of 52-week high91%8

1-year return+4%5

3-year return+103%8

5-year return-4%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 4% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+16%) and so far this year (+15%).

WATCH

Average long-term results. Multi-year returns are middling (+103% over three years and -3.6% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on BeOne Medicines AG. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ONCBeOne Medicines

Revenue FY25$5.3B

GROWTH RATING↗

VERY STRONG95 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+56%10

Revenue, next 1Y+27%9

Revenue, next 3Y, CAGR+18%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+194%10

EPS growth, FY27E+43%9

EPS growth, FY28E+33%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 95% of companies worldwide.

Revenue grew 56%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 18%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 43%/yr vs revenue 18%/yr), so margins should widen.

WATCH

Revenue grew 56%/yr over the last 3 years; forecasts see it cooling to 18%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

ONCBeOne Medicines

Total return Current1053%

Price return Current1053%

MOMENTUM RATING↗

STRONG73 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%7

3-month return+16%9

YTD return+15%7

MID & LONG-TERM▾SCORE

% of 52-week high91%8

1-year return+4%5

3-year return+103%8

5-year return-4%3

MOMENTUM ASSESSMENT

STRENGTHS

It's up 4% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+16%) and so far this year (+15%).

WATCH

Average long-term results. Multi-year returns are middling (+103% over three years and -3.6% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on BeOne Medicines AG. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community